About The Redwood Study

The Redwood Study is a phase 3 clinical research study for adults ages 18 to 75 who have Alpha-1 Liver Disease. The goal of the study is to evaluate the safety and effectiveness of an investigational study drug called fazirsiran.

Fazirsiran is being studied to understand whether it may help reduce liver scarring caused by Alpha-1 Liver Disease. In this study, fazirsiran is compared with a placebo, which contains no active medication. Comparing these two groups helps researchers better understand how the investigational study drug works and how safe it is.

About the Investigational Study Drug

There is currently no approved treatment for Alpha-1 Liver Disease. Fazirsiran is an investigational study drug being studied to see if it can reduce the production of an abnormal protein called Z-AAT, which can build up in the liver and cause scarring.

Who Can Participate?

You may be eligible to participate in The Redwood Study if you meet the following criteria:

Are 18 to 75 years of age
Have a confirmed diagnosis of Alpha-1 Liver Disease

A participating research site will review all study requirements with you. They will go over your medical history, perform study-related tests, answer all your questions, and confirm whether you meet all study requirements.

See if you prequalify

Study Design

The Redwood Study is a randomized, double-blind, placebo-controlled trial. This means participants are assigned by chance to receive either fazirsiran or a placebo. The study lasts approximately four and a half years.

Screening period

The screening period lasts up to 10 weeks and includes at least one or more study visits. During this time, the study team will review your medical history and perform tests and procedures, such as blood tests and imaging, to determine whether you are able to participate. If you meet all requirements, you can choose to join the study.

Treatment period

The treatment period lasts up to four years and includes up to 20 visits to the study site. Participants are randomly assigned to receive either fazirsiran or a placebo. Both are given as injections. During the first year of the study, there are monthly phone check-ins between in-person visits to monitor your health and answer questions.

Safety follow-up period

After the final dose of study treatment, participants enter a safety follow-up period that lasts up to six months. This period includes two study visits so the study team can continue to monitor your health and collect important safety information.

Patient Resources

Explore these resources to learn more about The Redwood Study. These materials can help you, your family, and your doctor understand the study and decide whether participation may be right for you.